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NATURAL HISTORY OF TRICUSPID REGURGITANT JET VELOCITY AND 
A NEW ASSOCIATION WITH PROTEINURIA IN CHILDREN WITH SICKLE 
CELL DISEASE. Suzanne J. Forrest, Judith L. Carbonella, Farzana D. Pashankar, 
Section of Hematology and Oncology, Department of Pediatrics, Yale University, School 
of Medicine, New Haven, CT. 
 
Given the morbidity and mortality associated with pulmonary hypertension and 
progressive renal failure in sickle cell disease, recognition of both organ dysfunctions 
during childhood should allow for improved management of patients and early treatment 
for both.  The definitive diagnosis of pulmonary hypertension is made on cardiac 
catheterization, however measurement of tricuspid regurgitant jet velocity (TRV) on 
echocardiogram can be used to estimate pulmonary artery systolic pressures and can be 
used as a screening modality for pulmonary hypertension.  Pulmonary hypertension is 
defined as TRV ! 2.5 m/sec and occurs in 16-30% of children with sickle cell disease on 
screening echocardiograms.  Two studies were conducted on a cohort of children from 
the sickle cell program at Yale New Haven Children’s Hospital.  The first study was 
conducted to determine the longitudinal natural history of TRV in untreated children with 
sickle cell disease (N=100 patients).  A detailed retrospective chart review was conducted 
on all sickle cell patients screened with echocardiograms from June 2005 to November 
2012.  Patients aged 6-21 years were included, 87 with HbSS and 13 with S!° 
thalassemia. At baseline, 67% of patients (N=67) had normal TRV <2.5 m/sec and 33% 
of patients (N=33) had elevated TRV !2.5 m/sec on screening echocardiogram.  Follow 
up echocardiograms were available for 82% of patients (82 of 100), and the median 
follow up time was 3.59 years.  On follow up, 61.40% (N=35) of patients with baseline 
normal TRV continued to have normal TRV on all subsequent echocardiograms, whereas 
38.60% (N=22) of patients had at least 1 echocardiogram with an elevated TRV.  Risk 
 !
factors associated with TRV conversion were baseline low O2 saturation, low 
hemoglobin and high reticulocyte count (all P <0.05).  On follow up, 32% (N=25) of 
patients with elevated TRV at baseline continued to have elevated TRV on all subsequent 
echocardiograms, whereas 68% (N=17) of patients had at least 1 echocardiogram with 
normal TRV without intervention.  Risk factors associated with persistent TRV elevation 
were baseline elevated TRV, low hemoglobin, and high white blood count (all P <0.05).  
Three of the 100 patients died during the follow up period, one with elevated TRV.  A 
second study was conducted to determine whether elevated TRV was associated with 
proteinuria in children with sickle cell disease (N=85 patients).  A detailed chart review 
was conducted on sickle cell patients screened with both echocardiograms and urinalysis 
from June 2005 to July 2010.  Longitudinal data from subsequent echocardiograms and 
urine analyses were also collected.  On initial echocardiograms, 32.9% (N=28) had an 
elevated TRV ! 2.5 m/sec. At initial screening 7.14% (N=2) of these patients with 
elevated TRV had proteinuria, compared to only 1.75% (N=1) without elevated TRV 
(P=0.25).  On follow up, 19.08% of repeat urinalysis showed proteinuria in patients with 
elevated baseline TRV compared to 12.35% in patients with normal baseline TRV 
(P=0.04).  Our first study revealed that patients with elevated TRV should be followed 
longitudinally prior to initiating treatment, as many patients will have normalization of 
TRV without intervention.  The first study also showed that patients with high hemolytic 
rate as evidenced by low hemoglobin and high reticulocyte count are at high risk of TRV 
conversion and should be monitored closely.  Our second study found a new association 
between elevated TRV and proteinuria in children with sickle cell disease followed 
longitudinally. 
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INTRODUCTION 
 
Overview of Sickle Cell Disease 
 Approximately 90,000 people live with sickle cell disease in the United States with 
an estimated 1 in 2,500 children is born with a form of sickle cell disease each year (1, 2).  
Sickle cell hemoglobinopathy is a heterogeneous set of diseases characterized by the 
presence of at least one hemoglobin ! globin gene affected by the sickle mutation (2).  
Hemoglobin, the protein within a red blood cell that carries oxygen, is composed of four 
globin chains, two " globin and two ! globin chains.  Sickle cell disease occurs when an 
offspring inherits either two sickle ! globin genes or one sickle ! globin gene in 
combination with another ! globin chain mutation (2, 3).  Approximately 60-65% of 
sickle cell disease patients are homozygous for the sickle mutation and have HbSS 
disease.  The most common compound heterozygote state, affecting approximately 25-
30% of patients with sickle cell disease is sickle hemoglobin-C disease.  Another form of 
sickle cell disease, representing approximately 5-10% of patients with 
hemoglobinopathies, is caused by coinheritance of a ! thalassemia mutation with the 
sickle mutation which results in S!° thalassemia (2).  Patients with HbSS disease and S!° 
thalassemia, who completely lack normal ! globin production, are generally more 
severely affected than patients with SC disease (3).  For the purposes of this thesis, sickle 
cell disease refers to patients with HbSS and S!° thalassemia.   
 Sickle cell disease can affect any organ in the body.  The principal clinical 
manifestations of patients with sickle cell disease are hemolytic anemia, episodes of 
vaso-occlusion, and increased susceptibility to infection (4, 5).  These pathologic 
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processes are a result of deoxygenation of the hemoglobin S molecule, which forms an 
intracellular polymer aggregate, ultimately causing the red cell to sickle (6).  The sickle 
cell mutation, a single nucleotide change in the coding region of the ! globin gene, 
results in an amino acid change from glutamic acid to valine.  The amino acid change 
from a hydrophilic glutamic acid to a hydrophobic valine residue is what causes protein 
polymerization in a deoxygenated state (2).  The sickled red blood cells can obstruct the 
microvasculature and, unlike normal red blood cells are more likely to adhere to the 
vascular endothelium (7, 8).  Both of these processes contribute to and ultimately cause 
vaso-occlusion, which results in organ injury and pain.  
 The prognosis for children born with sickle cell disease has drastically changed 
over the last three decades.  In 1967 more than 50% of children with sickle cell disease 
died before the age of 20 (9, 10).  With the advent of newborn screening, pneumococcal 
prophylaxis, and better comprehensive care, at least 90% of children born with sickle cell 
disease now survive past their 20th birthday (8, 11).  A study of 3764 patients with HbSS 
disease published in the New England Journal of Medicine by Platt et al. in 1994 reported 
a mean life expectancy of 42 years for males and 48 years for females with HbSS disease 
(12).  With more sickle cell disease patients surviving into adulthood, the frequency of 
end organ complications has increased (11, 13).  Thus, it is important to understand the 
natural history of end organ dysfunction in children with sickle cell disease and develop 
an approach to identifying children early who may be at increased risk of end organ 
disease.  With early identification and potential intervention, we may be able to decrease 
the morbidity and mortality these children would face as adults.   
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 Elevated Tricuspid Regurgitant Jet Velocity 
 Pulmonary hypertension occurs in approximately one third of adults with sickle cell 
disease and is associated with significantly increased morbidity and mortality (14, 15).  A 
clinical diagnosis of pulmonary hypertension can be hard to ascertain given the non-
specific symptoms, which include fatigue, shortness of breath, and increased heart rate.  
The definitive diagnosis of pulmonary hypertension is made by right heart catheterization 
with measurement of exact pulmonary artery pressures; however, this is an invasive and 
expensive procedure with associated risks.  Cardiac catheterization is therefore not a 
suitable method for screening for pulmonary hypertension.  Pulmonary artery systolic 
pressures can be estimated by measurement of tricuspid regurgitant jet velocity (TRV) on 
echocardiogram with the use of the modified Bernoulli equation (16).  Without structural 
obstruction to pulmonary blood flow, the right ventricular systolic pressure equals the 
pulmonary artery systolic pressure.  Studies have found that estimates of pulmonary 
artery systolic pressure by Doppler echocardiography are well correlated with more 
precise measures during cardiac catheterization (17, 18).  The specificity of elevated TRV 
to diagnose pulmonary hypertension increases as TRV increases.  A recent study in a 
small number of adults with sickle cell disease (N=25) found that the specificity of TRV 
of 2.51 m/sec in diagnosing pulmonary hypertension was 18.8%, whereas with a TRV of 
2.88 m/sec the specificity increased to 81% (19).  Doppler echocardiography can thus be 
used as a noninvasive way to identify patients who have or may be at risk for developing 
pulmonary hypertension.   
 In adults with sickle cell disease, elevated TRV is the strongest predictor of 
mortality versus other markers (20).  The first study of TRV in adults with sickle cell 
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disease was published in 1994 in a retrospective longitudinal analysis of 60 patients (21). 
Over a mean follow up period of 22 months, the study found that mortality was 
significantly greater in patients with pulmonary hypertension, defined in the study as 
TRV !2.5 m/sec.  Remarkably, 5 of 12 (42%) of the patients with pulmonary 
hypertension died during the follow up versus only 4 of 48 (8%) of the patients without 
pulmonary hypertension.  The study found a statistically significant increase in mortality 
in the patients with TRV !2.5 m/sec (P=0.03).  In addition, multivariate analysis revealed 
that elevated TRV was an independent predictor of death, whereas other variables 
including older age, lower hematocrit, and cardiac symptoms were not independent 
predictors of death (21).  Furthermore, a prospective cross-sectional study published in 
2004 by Gladwin and colleagues showed that elevated TRV (!2.5 m/s) had a prevalence 
of 32%, and predicted approximately a ten-fold increased risk for early mortality in adults 
with sickle cell disease (16).   
 Post mortem studies suggest that the pathological changes that result in pulmonary 
hypertension in adults are chronic and may start during childhood (22-24).  One study 
published in 2001 by Adedeji and colleagues looked at pulmonary pathology in 12 sickle 
cell patients at autopsy (23).  The objective of the study was to investigate the potential 
role that pulmonary embolism or small vessel arterial thrombosis play in the development 
of pulmonary hypertension in sickle cell disease (23).  The authors found that the most 
common pulmonary findings were thrombotic arteriopathy of small pulmonary arteries, 
which were present in 9 of the 12 patients.  In all 9 patients they found right ventricular 
hypertrophy, and in 8 of the 9 cases they found small arterial changes that were consistent 
with pulmonary hypertension.  The authors commented that it was possible the findings 
9 
!
in the small arteries were from recurrent small pulmonary embolisms, but that the 
histology of fresh thrombi likely showed sickled red blood cells within the fibrinous 
developing clots (23).  They concluded that there appears to be a progression from early 
pulmonary alterations in childhood to obliterative vasculopathy in adults that is 
irreversible.   
 
Elevated TRV in Children With Sickle Cell Disease 
 Multiple pilot studies of children with sickle cell disease showed that they had a 
similar prevalence of elevated TRV as adults.  Studies in children report a 16–30% 
prevalence of elevated TRV !2.5 m/sec on screening echocardiograms (25-27).  Early 
diagnosis of increased pulmonary artery pressures and treatment during childhood may 
help to reverse these changes and reduce the morbidity and mortality correlated with 
elevated TRV in adults with sickle cell disease.  Further characterization of the natural 
history and progression of TRV in children with sickle cell disease is critical to early 
diagnosis and treatment.  
 A prospective study published in 2008 by Dr. Pashankar and colleagues found that 
low oxygen saturation, high reticulocyte count, and high platelet count were significantly 
associated with elevated TRV (25).  While there have been multiple cross-sectional 
studies, there have not been any studies to assess the natural history of TRV in children 
with sickle cell disease followed longitudinally for many years.  It is not known what 
happens to patients with and without elevated TRV on baseline screening 
echocardiogram over time.  Studying the cohort of sickle cell children followed at Yale 
offered us the ability to track TRV over time, and try to identify what potential factors 
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place children at risk of having persistent elevation of TRV, or converting from normal to 
elevated TRV over time.  Longitudinal analysis of this patient population can help to 
guide the timing of performing certain screening tests, and how to predict which children 
may need to be closely monitored for the development of end organ dysfunction over 
time.    
 
Treatment of Elevated Tricuspid Regurgitant Jet Velocity 
 There is no effective treatment for adults with sickle cell disease who have 
pulmonary hypertension, and it is thought to be irreversible (28, 29).  Sildenafil, a 
selective pulmonary vasodilator, was investigated in a double blind placebo controlled 
study as a potential treatment for elevated TRV in adults with sickle cell disease.  
Unfortunately, the trial was stopped early because of an increase in acute pain episodes in 
the treatment group (35%) as compared to the placebo group (14%) (29).  Other 
treatments are currently being investigated, but there remain no FDA approved drugs for 
adults with sickle cell disease related pulmonary hypertension.  There have been limited 
studies in children as to whether elevated TRV is potentially reversible with treatment.  It 
is possible that initiation of treatment earlier in the course of elevated TRV may be more 
effective.   
 Hydroxyurea is the only FDA approved medication for the treatment of sickle cell 
disease in the United States (30, 31).  Hydroxyurea is used commonly to treat sickle cell 
disease patients for indications including frequent vasooclusive crises, acute chest 
syndrome, priapism, and severe anemia (30, 32, 33).  Hydroxyurea treatment is thought 
to be effective by increasing the amount of fetal hemoglobin, which then reduces red 
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blood cell adhesion and decreases hemolysis (34-36).   
 In 2008, Dr. Pashankar and her team published a small pilot study, which assessed 
the effect of hydroxyurea on elevated TRV in children with sickle cell disease.  Five 
patients who had persistent elevated TRV >2.5m/s were treated with hydroxyurea.  
Echocardiograms were repeated every 6-12 months for a mean follow up of 24 months.  
TRV decreased from 3.16±0.27 to 2.64±0.20 (P=0.017) after 3-6 months and to 
2.42±0.26 mmHg (P=0.002) after 9-12 months on treatment (37).  Based on these 
preliminary findings, a prospective clinical trial was started at three centers including 
Yale New Haven Children’s Hospital.   
 
Pathogenesis and Study of Outcomes Associated with Elevated TRV 
 The exact pathogenesis of pulmonary hypertension is unknown and likely 
multifactorial, with hemolysis induced nitric oxide depletion and vascular dysfunction 
likely playing major role.  Potential mechanisms for the development of pulmonary 
hypertension include hypoxemia, repeated thrombotic embolism, iron overload, and 
intravascular and parenchymal sequestering of red blood cells (16, 38-41).  Recent 
studies have highlighted the potential importance of inflammation in the pathogenesis of 
pulmonary hypertension (42, 43).   
 Patients with sickle cell disease are at risk not only of pulmonary complications, 
but dysfunction of other organs, as the disease is systemic and can impact any organ in 
the body.  Multiple studies tried to identify risk factors associated with elevated TRV in 
children with sickle cell disease, though few have looked at clinical correlates or 
outcomes associated with elevated TRV.  The questions remain: are children with 
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elevated TRV more likely to develop other end organ dysfunction?  Do children with 
elevated TRV, like their adult counterparts, have an increased mortality risk?   
 
Sickle Cell Nephropathy 
 Like pulmonary hypertension, the development of sickle cell nephropathy is of 
significant concern in adults with sickle cell disease.  Renal failure affects approximately 
12–21% of adults with sickle cell disease, and is associated with decreased survival (11, 
44, 45).  Approximately 25% of patients with sickle cell disease and end stage renal 
disease die within the first year of starting dialysis (46).  Renal involvement in sickle cell 
disease is first characterized by a reversible urinary concentrating deficit, then a fixed 
concentrating defect leading to polyuria (45, 47-49).  Over time, glomerular hypertrophy 
with a high GFR and increased renal blood flow leads to focal segmental 
glomerulosclerosis, microalbinuria/proteinuria, hematuria, and ultimately renal failure in 
many patients (45, 50-52).   
 One of the earliest manifestations of sickle cell nephropathy is microalbinuria/ 
proteinuria (53).  The onset of proteinuria has been reported in early childhood, and 
studies in children report a prevalence of microalbuminuria of 16-26% and a prevalence 
of proteinuria of 6.2% (54-56).  One study published in 2007 by McKie et al. in children 
with sickle cell disease aged 3-20 reported that lower hemoglobin and older age were 
significant associated with the presence of microalbinuria or proteinuria (54).  The mean 
hemoglobin with microalbuniria or proteinuria (N=37) was 7.71 g/dL versus 8.54 g/dL in 
children without any urinary protein (N=154) (P=0.0004) (54).  Additional risk factors 
significantly associated with proteinuria in children with sickle cell disease reported from 
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other studies include type of sickle cell disease, history of acute chest syndrome, and 
stroke (55, 56).   
 
Elevated TRV and Proteinuria  
 A study published in 2010 in adults with sickle cell disease found a positive 
association between albuminuria and elevated TRV.  The study reported that TRVs were 
significantly higher (mean 3.15 m/s) in patients with macroalbuminuria (N=15) when 
compared to patients with microalbuminuria or normalbuminuria (N=58) (mean 2.45 
m/s) (P=0.00068) (57).  Prior to our study, there was no data in children on the potential 
association between kidney dysfunction manifested by proteinuria and elevated 
pulmonary artery pressures as measured by TRV.  We thus conducted our final study to 
determine if elevated pulmonary artery systolic pressure, as estimated by 
echocardiogram, was associated with proteinuria in children with sickle cell disease.   !  
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PURPOSE 
 To determine the natural history of TRV in untreated children with sickle cell 
disease, and to determine if elevated TRV is associated with proteinuria in children with 
sickle cell disease.   
 
HYPOTHESES 
Untreated children with elevated TRV (!2.5 m/sec) will continue to be more likely to 
have elevated TRV overtime.  A proportion of children with sickle cell disease who 
previously had normal TRV will go on to develop elevated TRV.  Children with elevated 
TRV are more likely to have or develop proteinuria.  
 
SPECIFIC AIMS 
1. To determine whether untreated children with elevated TRV (!2.5 m/sec) are likely 
to have elevated TRV when followed longitudinally.  
2. To determine what proportion of children with sickle cell disease who previously had 
normal TRV will go on to develop elevated TRV, and what risk factors may be 
associated.   
3. To determine if elevated TRV is associated with proteinuria.   
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METHODS 
 
 The author of this thesis was not involved in designing the yearly assessments, 
which were conducted on children with sickle cell disease followed by the Yale New 
Haven Hospital Pediatric Sickle Cell Program since 2005.  The author did not collect the 
primary data used for the studies, which was collected during clinic visits.  Pediatric 
Cardiologists were responsible for reading and interpreting the echocardiograms and 
determining the TRV (if applicable).  The author was responsible for abstracting primary 
data from the paper and electronic medical records for each patient involved in the 
studies, creating a de-identified database of all of clinical information, and performing all 
statistical analysis completed as part of the studies.  All aspects of the investigations were 
supervised by Farzana Pashankar, MD.  
 
1. Patient Population 
 The patient population for the two studies included children from the sickle cell 
program at Yale New Haven Children’s Hospital, which follows children with sickle cell 
disease in southern Connecticut.  Patients in this program are seen at least annually for a 
comprehensive assessment, during which a detailed clinical history, a complete physical 
examination, and annual screening laboratory tests are performed.  The clinical history 
included documenting history of 1) acute chest syndrome 2) stroke 3) chronic blood 
transfusions 4) treatment with hydroxyurea.  The laboratory tests done during these visits 
are those recommended by the American Academy of Pediatrics (58).  The laboratory 
tests included complete blood count, reticulocyte count, direct and total bilirubin levels, 
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lactate dehydrogenase, serum urea nitrogen, creatinine level, and urinanalysis. Vital signs 
were also measured during the visits including heart rate, blood pressure, respiratory rate, 
and oxygen saturation by pulse oximetry.  Transcranial Dopplers were performed on 
patients with HbSS or S!° thalassemia between the ages of 2 and 14 years old as part of 
screening for stroke.  Starting in 2005, screening echocardiograms were conducted as part 
of the annual comprehensive assessment for children older than 6 years with HbSS or S!° 
thalassemia.  Echocardiograms were performed as an outpatient visit at the Pediatric 
Echocardiography Laboratory when patients were in a steady state, at least 2 weeks after 
hospital admissions for vasoocclusive crises.  The studies were approved by the 
institutional review board (IRB) at Yale University School of Medicine.  
 
2. Echocardiography 
 Two-dimensional Doppler echocardiography was performed for all patients using 
the Philips IE33 ultrasound system (Philips Medical Systems, Bothell, WA) or the 
Acuson Sequoia Ultrasound System (Siemens Medical Solutions, Malvern, PA).  
Selection of appropriate transthoracic transducer was made during the evaluation.  
Cardiac measurements were performed according to the guidelines of American Society 
of Echocardiography.  TRV was measured by pulsed-wave and continuous-wave Doppler 
echocardiography where applicable.  Multiple views (apical 4-chamber, parasternal short 
axis, parasternal long axis) were obtained to record optimal tricuspid Doppler flow 
signals, and a minimum of 5 sequential signals were recorded.  The right ventricular to 
right atrial systolic pressure gradient was calculated using the modified Bernoulli 
equation (4 x V2).  Pulmonary artery systolic pressure was quantified by adding the 
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Bernoulli-derived right ventricular systolic peak pressure to the estimated mean right 
atrial pressure (5 mm Hg).  Pulmonary artery diastolic pressure was estimated by 
measurement of the end diastolic velocity of the pulmonary insufficiency jet by similar 
Doppler techniques.  A peak TRV of 2.5 m/sec equating to a pulmonary artery pressure 
of at least 30 mmHg was considered to be elevated.  Peak TRV of 2.5 m/sec has been 
previously used in studies of pulmonary hypertension in both adults and children with 
sickle cell disease (16).  Patients with no measurable TRV or TRV <2.5 m/sec were 
considered to have normal pulmonary artery pressures, and these patients were 
categorized as having normal TRV.  
 
3. Study of the Natural History of TRV in Children with Sickle Cell Disease 
 For this study, charts including data from June 2005 to November 2012 were 
reviewed.  Patients with HbSS and S!° thalassemia who had screening echocardiograms 
were included in the study.  Patients with pulmonary stenosis or other structural 
obstruction to pulmonary blood flow were excluded.  Patients who were on chronic 
transfusions or hydroxyurea prior to their first echocardiogram were included in the 
study.  Follow up echocardiogram data was censored for patients who started 
hydroxyurea or chronic transfusions after their first screening echocardiogram.  If a 
patient subsequently stopped taking the medication, there echocardiograms continued to 
be censored and were not included in the analysis.  Data collected included baseline 
demographics, type of sickle cell disease, clinical history, echocardiogram results, and 
laboratory results.  Longitudinal data from all subsequent echocardiograms were 
collected. A database was created with de-identified data from each visit.  The database 
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included baseline clinical and laboratory data in addition to follow up echocardiograms 
and treatment data (for example, dates of hydroxyurea treatment).  For oxygen saturation 
data, when there was a range, the average was taken (for example, O2 sat 90-92% was 
recorded in the database as 91%).  For echocardiogram data, when there was a range for 
TRV, the lowest number was taken (for example, TRV 2.4-2.7 was recorded in the 
database as 2.4).  Data was analyzed using Chi square test for categorical variables and 
student t-test for continuous variables.  P value less than 0.05 was considered statistically 
significant.   
 
4. Study to Determine if Elevated TRV is Associated with Proteinuria  
 For this study, charts were reviewed from including data from June 2005 to July 
2010.  Patients who had a screening echocardiogram and a urinalysis within one year 
were included in the study.  Patients with pulmonary stenosis or other structural 
obstruction to pulmonary blood flow were excluded.  Baseline data collected included 
demographics, type of sickle cell disease, clinical history, echocardiogram results, 
laboratory results, and urinalysis.  Urinalysis was sent for measurement of protein, which 
was quantified from 0 to 3+. Urine protein 1+ equaled 30 mg/dl, 2+ equaled 100 mg/dl, 
and 3+ equaled 300 mg/dl in our laboratory.  Urine protein of 1+ to 3+ was considered 
positive, urine protein of 0 was considered negative.  Longitudinal data from all 
subsequent echocardiograms and urinalyses for each subject were also collected.  On 
follow up, urinalysis was repeated at least annually.  Echocardiograms were repeated 
annually on patients with a baseline TRV !2.5 m/sec, and every two years on patients 
with normal baseline TRV.  Data was analyzed using Chi square test for categorical 
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variables and student t-test for continuous variables.  P value less than 0.05 was 
considered statistically significant.   
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RESULTS 
 
Study 1. Natural history of TRV in Children with Sickle Cell Disease 
Baseline Characteristics 
 A total of 100 patients aged 6-21 years were included, 87 with HbSS and 13 with 
S!° thalassemia.  The male to female ratio was 1.22:1.  The mean age at initial screening 
echocardiogram was 11.82 years (standard deviation was 4.16 years).  On initial 
screening echocardiograms, 67 of 100 patients (67%) had normal TRV <2.5 m/sec and 33 
of 100 patients (33%) had elevated TRV !2.5 m/sec.  Table I shows the baseline 
characteristics of patients with and without elevated TRV on initial screening 
echocardiogram (ECHO).  
TABLE I. Characteristics of Patients With and Without TRV on Baseline Screening Echocardiogram 
 
Baseline TRV 
  <2.5 m/sec !2.5 m/sec  
Patient Characteristics (n = 67) (n = 33) P value 
Age at initial ECHO, mean ± SD, y  11.60 ± 3.83 12.33 ± 4.80 0.21 
Male gender, n (%) 37 (55.22) 18 (54.55) 0.88 
Genotype, n (%)    
    SS 55 (82.09) 32 (96.97)  
    S"° 12 (17.91) 1 (3.03)  
H/O acute chest syndrome, n (%) 23 (34.33) 14 (42.42) 0.57 
H/O stoke, n (%)  9 (13.43) 1 (3.03) 0.20 
Hydroxyurea, n (%) 15 (22.39) 6 (18.18) 0.82 
Blood transfusion, n (%) 11 (16.42) 2 (6.06) 0.25 
Systolic BP, mean ± SD, mmHg 108.37 ± 7.63 108.63 ± 8.91 0.44 
Oxygen saturation, mean ± SD 97.19 ± 2.38 95.83 ± 3.80 0.01* 
Hemoglobin, mean ± SD 8.70 ± 1.32 8.38 ± 1.01 0.12 
Hematocrit, mean ± SD 25.05 ± 4.30 23.43 ± 3.40 0.07 
Reticulocyte count, mean ± SD 10.09 ± 4.78 12.22 ± 5.66 0.04* 
WBC count (x10^3/µ), mean ± SD 12.79 ± 5.04 12.48 ± 3.83 0.38 
Platelet count, mean ± SD 414.78 ± 139.69 508.82 ± 140.76 0.001* 
LDH, mean ± SD 602.71 ± 245.43 637.50 ± 230.38 0.38 
Creatinine, mean ± SD, mg/dl 0.51 ± 0.15 0.47 ± 0.16 0.09 
*P < 0.05.    !
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 As shown in Table I, low daytime oxygen saturation, high reticulocyte count, and 
high platelet count were significantly associated with elevated TRV (all P < 0.05).  In the 
group with elevated TRV, 32 of 33 (96.97%) of the patients had HbSS disease, whereas 
only one of 33 (3.03%) of the patients had S"° thalassemia.  In the group with normal 
TRV, 12 of 67 patients (17.91%) had S"° thalassemia.  History of acute chest syndrome 
and history of stroke were not significantly different between patients with and without 
elevated TRV.  Similarly, other laboratory measures including hemoglobin, hematocrit, 
white blood cell count, lactate dehydrogenase, and creatinine were not statistically 
different between the two groups.   !
Longitudinal Follow Up of Echocardiograms  
 Repeat echocardiograms were available for 82% of patients (82 of 100) in the 
study.  The total follow up time was 283.23 years and the median follow up time per 
patient was 3.59 years (range 0.11-7.32 years).  The total number of repeat 
echocardiograms was 230 with an average number of 2.80 follow up echocardiograms 
per patient.  As shown in Table II, 61.40% (N=35) of patients with baseline normal TRV 
continued to have normal TRV on all subsequent echocardiograms, whereas 38.60% 
(N=22) of patients had at least 1 echocardiogram with an elevated TRV.  Follow up 
echocardiograms were available for 25 of 33 patients (75.76%) with elevated TRV at 
baseline.  On follow up, 32% (N=8/25) of patients continued to have elevated TRV on all 
subsequent echocardiograms, whereas 68% (N=17) of patients had at least 1 
echocardiogram with normal TRV without intervention.  Patients with a TRV !2.5 m/sec 
on initial echocardiogram had a significantly higher chance of having repeat 
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echocardiograms with elevated TRV compared to patients with normal baseline TRV 
(P<0.0001).  Patients with a TRV !2.5 m/sec on initial echocardiogram also had a 
significantly higher chance of having persistent elevation of TRV on all follow up 
echocardiograms (P=0.04).   
 
 Based on the follow up echocardiogram data, patients were divided into four 
groups.  The objective of creating the four groups was to 1) determine potential factors 
associated with TRV conversion from normal to elevated 2) identify potential factors 
associated with persistent TRV elevation.  The following were the four groups.   
1) Patients with baseline TRV <2.5 m/sec who continued to have TRV <2.5 m/sec on 
all repeat echocardiograms (N=35).  This group was labeled Low-low.  
2) Patients with baseline TRV <2.5 m/sec who had at least 1 repeat echocardiogram 
with TRV >2.5 m/sec (N=22). This patient was labeled Low-high.  
3) Patients with baseline TRV !2.5 m/sec who continued to have TRV !2.5 m/sec on 
all repeat echocardiograms (N=8). This group was labeled High-high.  
4) Patients with baseline TRV 2.5 m/sec who had at least 1 repeat echocardiogram 
with TRV <2.5 m/sec (N=17). This group was labeled High-low.  
TABLE II. Follow Up ECHOs in Patients With and Without Elevated TRV on Baseline Screening ECHO 
 Baseline TRV  
 
Patient characteristics 
<2.5 m/sec 
(n = 67) 
!2.5 m/sec 
(n = 33) P value 
Patients with follow up ECHO, n (%) 57 (85.07) 25 (75.76)  
Total number of years  212.28 70.95  
Average number of years per patient 3.72 2.84  
Total number of ECHOs 140 90  
Number of ECHOs per patient 2.46 3.60  
Number of patients with TRV <2.5 m/sec on all repeat ECHOs (%) 35 (61.40) 3 (12.00) 
<0.0001* 
Number of patients with TRV ! 2.5 m/sec on at least 1 repeat ECHO (%) 22 (38.60) 22 (88.00) 
Number of patients with TRV ! 2.5 on all repeat ECHOs (%)  6 (10.53) 8 (32.00) 0.04* 
Number of repeat echocardiograms with TRV < 2.5 m/sec, n (%) 100 (71.4) 29 (32.2) 
<0.0001* 
Number of repeat echocardiograms with TRV ! 2.5 m/sec, n (%) 40 (28.6) 61 (67.8) 
*P < 0.05.    
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 Table III shows the characteristics of the each of the four groups: Low-low, Low-
high, High-high, High-low.  Of note, 62.5% of the patients in the High-high group were 
started on hydroxyurea after at least two echocardiograms with elevated TRV !2.5 m/sec.  
Three patients died during the follow up period of the study, one in the low-low group 
and two in the low-high group.  All three patients had HbSS disease.   
 
TABLE III. Characteristics of Four Longitudinal Follow Up Groups 
 Low-low (N = 35) 
Low-High 
(N = 22) 
High-high 
(N = 8) 
High-low 
(N = 17) 
Total number of ECHOs 94 103 24 66 
Average number of ECHOs per patient 2.69 4.68 3.00 3.88 
Total number of years 108.57 103.71 12.73 58.22 
Average number of years per patient 3.10 4.71 1.59 3.42 
Number of ECHOs <2.5 94 63 0 29 
Number of ECHOs !2.5 0 40 24 37 
# patients with 1 ECHO >2.5 0 11 0 4 
# patients with 2 ECHO >2.5 0 7 4 7 
# patients with 3 ECHO >2.5 0 2 2 5 
# patients with 4 ECHO >2.5 0 1 3 1 
# patients with 5 ECHO >2.5 0 1 0 0 
# patients started on HU during study 9 1 5 3 
# patients deceased during study 1 2 0 0 
% of patients started on HU 25.71% 4.55% 62.5% 17.65% 
 
  
 As shown in Table IV and Table V, baseline factors including clinical and 
laboratory data were examined for differences between the Low-low group and Low-high 
group to determine risk factors for TRV conversion.  Baseline factors were also examined 
between the High-high group and the High-low group to determine factors associated 
with persistent elevation of TRV.  Significant risk factors associated with TRV 
conversion from normal to elevated were baseline low O2 saturation, and high 
reticulocyte count (all P <0.05).  High white blood cell count was trending towards a 
significance as a risk factor associated with TRV conversion (P=0.07).   
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TABLE IV. Risk Factors Associated with TRV Conversion 
Baseline Characteristics 
Low-low 
(N = 35) 
Low-high 
( N = 22) P value 
TRV, mean ± SD 2.20 ± 0.17 2.27 ± 0.16 0.09 
Age, mean ± SD 11.87 ± 3.67 11.32 ± 4.05 0.30 
O2 Saturation, mean ± SD 97.71 ± 2.33 95.86 ± 2.59 0.004* 
Hemoglobin, mean ± SD 8.80 ± 1.42 7.89 ± 1.07 0.12 
Reticulocyte count, mean ± SD 8.47 ± 3.66 13.61 ± 4.88 0.0001* 
WBC count (x10^3/µ), mean ± SD 12.26 ± 5.64 14.47 ± 4.60 0.07 
Platelet count, mean ± SD 401.29 ± 119.39 438.05 ± 178.63 0.18 
*P < 0.05.    
 
As shown in Table V, significant risk factors associated with persistent TRV elevation 
were baseline TRV, hemoglobin, and white blood cell count (all P <0.05).  Lower oxygen 
saturation was trending towards significance as a factor associated with persistent TRV 
elevation (P=0.06)  
TABLE V. Risk Factors Associated with Persistent TRV Elevation 
Baseline Characteristics 
High-high 
(N = 8) 
High-low 
(N = 17) P value 
TRV, mean ± SD 2.79 ± 0.15 2.63 ± 0.15 0.02* 
Age, mean ± SD 14.58 ± 5.13 12.07 ± 4.04 0.09 
O2 Saturation, mean ± SD 94.43 ± 4.79 96.91 ± 2.65 0.06 
Hemoglobin, mean ± SD 7.79 ± 1.01  8.83 ± 0.93 0.009* 
Reticulocyte count, mean ± SD 11.91 ± 2.41 10.39 ± 3.94 0.18 
WBC count (x10^3/µ), mean ± SD 14.96 ± 4.83 11.66 ± 3.26 0.03* 
Platelet count, mean ± SD 545.38 ± 212.97 489.47 ± 130.16 0.21 
*P < 0.05.    
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Study 2. Is Elevated TRV Associated with Proteinuria in Children with Sickle Cell 
Disease? 
 
Baseline Characteristics 
 A total of 85 patients aged 6–21 years were included in the study.  The baseline 
characteristics were similar to the Study 1.  Seventy-two patients had HbSS disease and 
13 patients had S!° thalassemia.  The male to female ratio was 1.36:1.  The mean age at 
initial screening echocardiogram was 12.16 years (standard deviation was 4.15 years).  
On initial screening echocardiograms, 28 of 85 patients (32.9%) had elevated TRV !2.5 
m/sec.  Table VI shows the baseline characteristics of patients with and without elevated 
TRV.  As shown in Table I, low daytime oxygen saturation, high reticulocyte count, and 
high platelet count were significantly associated with elevated TRV.  Of the 28 patients 
with elevated TRV, 2 patients (7.14%) had proteinuria compared to 1 of 57 patients 
(1.75%) with normal TRV.  This was not a statistically significant finding (P=0.25).   
TABLE VI. Characteristics of Patients With and Without High TRV on Baseline Screening ECHO 
 Baseline TRV  
 
Patient characteristics 
<2.5 m/sec 
(n = 57) 
!2.5 m/sec 
(n = 28) 
P value 
Age at echocardiogram, mean ± SD, y 11.72 ± 3.93 13.04 ± 4.45 0.17 
Male gender, n (%) 33 (57.89) 16 (57.14) 0.86 
Genotype, n (%)    
    SS 45 (78.9) 27 (96.43)  
    S"° 12 (21.0) 1(3.57) 0.22 
H/O acute chest syndrome, n (%) 23 (40.3) 16 (57.14) 0.15 
Hydroxyurea, n (%) 12 (21.0) 5 (17.86) 0.78 
Blood transfusion, n (%) 12 (21.0) 2 (7.14) 0.12 
Stroke/abnormal TCD, n (%) 10 (7.5) 1 (3.57) 0.09 
Systolic BP, mean ± SD, mmHg 108.42 ± 8.10 110.00 ± 7.63 0.39 
Oxygen saturation, mean ± SD 97.28 ± 2.45 95.56 ± 4.46 0.02* 
Hemoglobin, mean ± SD, g/L 8.45 ± 1.30 8.30 ± 1.09 0.60 
Hematocrit, mean ± SD 24.49 ± 4.13 23.11 ± 3.50 0.13 
Reticulocyte count, mean ± SD 10.43 ± 5.39 13.66 ± 6.73 0.040 
WBC count (x103/ml), mean ± SD 14.23 ± 5.34 13.53 ± 4.76 0.55 
Platelet count, mean ± SD 406.48 ± 143.08 505.39 ± 143.75 0.003* 
LDH, mean ± SD 648.21 ± 254.30 650.50 ± 255.18 0.98 
Total bilirubin, mean ± SD 3.25 ± 2.50 3.90 ± 2.51 0.30 
Creatinine, mean ± SD, mg/dl 0.52 ± 0.16 0.48 ± 0.16 0.25 
Positive urine protein, n (%) 1 (1.75) 2 (7.14) 0.25 
*P < 0.05.    
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Longitudinal Follow Up of Echocardiograms and Urinalysis 
 As shown in Table VII, when patients were grouped based on their initial screening 
echocardiograms, follow up urinalysis data was available in 92.86% of patients with 
elevated TRV and in 94.73% of patients with normal TRV.  The number of follow up 
urinalysis per patient was 6.17 in the high TRV group and 7.24 in the normal TRV group.  
Of the 173 repeat urine analyses in patients with elevated TRV, 19.08% were positive for 
proteinuria (P=0.04).   
TABLE VII. Follow Up Urinalysis in Patients With and Without High TRV on Baseline Screening ECHO 
 
Baseline TRV 
 
 
Patient characteristics 
<2.5 m/sec 
(n = 57) 
!2.5 m/sec 
(n = 28) 
P value 
Patients with follow up urinalysis, n (%) 54 (94.73%) 26 (92.86%  
Total number of urinalysis 413 173  
Number of urinalysis per patient 7.24 6.17  
Number of urinalysis with positive protein, n (%)  51 (12.35%) 33 (19.08) 0.04* 
*P < 0.05.    
 
 As shown in Table VIII, when patients were grouped based on the presence of any 
echocardiogram (baseline or follow up) having TRV !2.5 m/sec, follow up urinalysis 
were available in 95.35% of patients with elevated TRV and 92.86% of patients with 
normal TRV.  Of the 302 repeat urinalysis in patients with any elevated TRV, 21.52% 
were positive for proteinuria compared to 6.69% (19 of 284 urine samples) in patients 
with every TRV < 2.5 m/sec (P=<0.001). 
TABLE VIII. Follow Up Urinalysis in Patients With and Without High TRV on Any ECHO (Baseline or 
Follow Up) 
 
Baseline TRV 
 
 
Patient characteristics 
<2.5 m/sec 
(n = 42) 
!2.5 m/sec 
(n = 43) P value 
Patients with follow up urinalysis, n (%) 39 (92.86%)  41 (95.35%)  
Total number of urinalysis 284 302  
Number of urinalysis per patient 7.28 7.36  
Number of urinalysis with positive protein, n (%)  19 (6.69) 65 (21.52) <0.001* 
*P < 0.05.    
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DISCUSSION 
 
 Our first study showed that on initial screening echocardiogram 33% of patients 
had elevated TRV !2.5 m/sec.  Risk factors associated with increased TRV were similar 
to the study previously published by Dr. Pashankar and her group at Yale and included 
low daytime oxygen saturation, high reticulocyte count, and high platelet count, all of 
which are signs of increased hemolysis (25).  Other studies in have shown a similar 
association between low daytime oxygen saturation and elevated TRV (27, 59).  It is 
unclear whether hypoxia plays a direct role in the development of increased TRV in 
children with sickle cell disease.  Chronic hypoxia from multiple conditions predisposes 
patients to the development of pulmonary hypertension (60).  These conditions include 
chronic obstructive pulmonary disease, pulmonary fibrosis, sleep-disordered breathing, 
and exposure to high altitude.  In children with sickle cell disease and elevated TRV, 
hypoxia may play a direct role in the development of increased pulmonary artery 
pressures, as has been suggested in previous studies (27).  Alternatively, the relationship 
between low oxygen saturation and elevated TRV may not be a causative one.  Low 
oxygen saturation may indicate that these are patients with higher rates of hemolysis, who 
are therefore predisposed to the development of elevated TRV.  This indirect relationship 
is supported by the association between elevated TRV and other markers of hemolysis, 
including high reticulocyte and high platelet count.   
Over a median follow up time of 3.59 years, 61% of patients with normal TRV at 
baseline continued to have normal TRV, indicating that most patients who have normal 
TRV will continue to have normal TRV.  On follow up, there were a significant 
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proportion of patients, almost 40%, who had a normal baseline TRV, but subsequently 
had an elevated TRV !2.5 m/sec.  Interestingly, this group of patients was distinct in 
terms of other clinical measures from their counterparts who remained with normal TRV 
over time.  Risk factors associated with TRV conversion were baseline low oxygen 
saturation and high reticulocyte count (all P <0.05).  These are similar to the risk factors 
that put patients at increased risk of having elevated TRV at screening and suggest that 
patients who have laboratory or clinical markers of increased hemolysis may need to be 
monitored more closely and may need to have screening echocardiograms on an annual 
basis.  The finding that low oxygen saturation was a risk factor for TRV conversion again 
highlights the importance of monitoring children with lower oxygen saturation closely. 
Patients with normal TRV and no signs of increased hemolysis (low oxygen saturation, 
high reticulocyte count) can likely be screened with echocardiograms every 2 years, as 
opposed to annually, which is currently the suggested practice at the Yale Sickle Cell 
Program.   
For the 33% of patients with elevated TRV at baseline, follow up was available 
for 75.76% (25 of 33) of the patients.  There were ten patients who were started on 
hydroxyurea treatment after one echocardiogram with elevated TRV, and this 
substantially affected the follow up data available for this cohort.  On follow up of the 
children with elevated TRV at baseline 32% (N=8/25) of patients continued to have 
elevated TRV on all subsequent echocardiograms, whereas 68% (N=17) of patients had 
at least 1 echocardiogram with normal TRV without intervention.  This finding highlights 
that the reproducibility of TRV measurement is limited.  This was was previously shown 
by the Dr. Pashankar and other investigators (37, 61).  It is therefore important to repeat 
29 
!
echocardiograms and ensure that the elevated TRV is persistent before considering any 
therapeutic intervention.  Notably, despite the small patient size, significant risk factors 
associated with persistent TRV elevation were baseline TRV, hemoglobin, and white 
blood count.   
In adults with sickle cell disease elevated TRV is associated with multiple 
important clinical outcomes, of which the most notable is increased mortality (16, 62).  In 
addition, studies in adults with sickle cell disease with elevated TRV have found 
significant associations with pulmonary hypertension, decreased exercise capacity (Six-
minute walk test), leg ulcers ,and proteinuria (13, 16, 29, 63-66).  There have been 
limited studies in children with elevated TRV to investigate associations with clinical 
outcomes.  Sickle cell disease children with increased TRV do not appear to have the 
same increased risk of short-term mortality that adults with elevated TRV have.   
Two studies in children with sickle cell disease have looked at the clinical 
associations with elevated TRV.  One study published in 2009 in a cohort of children and 
adolescents with sickle cell disease (N=230) found that patients with elevated TRV had a 
decline in oxygen saturation during exercise with the six-minute walk test (P=0.0002) 
(27).  Unlike in adults, the study did not find an association between elevated TRV and 
decreased exercise tolerance as measured with the six-minute walk test (27).   Another 
study published in 2011 on children aged 3-20 years old found that over a median follow 
up of 22 months, baseline TRV elevation was associated with a 4.4-fold increase in the 
odds of a 10% or more decline in exercise tolerance (P=0.015).  Our study is the first to 
examine whether there is an association between elevated TRV and proteinuria in 
children with sickle cell disease.   
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 In our second study, urine protein was present in 2 (7.14%) patients with TRV !2.5 
m/sec compared to 1 (1.75%) patient with normal TRV.  This was not statistically 
significant, due to the small numbers in each group.  Interestingly, the patient with 
normal TRV who had proteinuria at baseline did have a borderline high TRV of 2.4–2.7 
m/sec on initial echocardiogram.  All of his subsequent echocardiograms showed a high 
TRV >3 m/sec, hence it is likely that the pulmonary artery pressures were evolving at the 
time of the initial echocardiogram.  
Follow up of urinalysis data showed a significant association between proteinuria 
and elevated TRV when patients were grouped either based on their initial 
echocardiogram or on any subsequent echocardiogram showing TRV !2.5 m/sec.  A 
positive association between proteinuria and pulmonary hypertension has been reported 
previously in adults (13, 57).  Ours is the first study showing that proteinuria is associated 
with elevated TRV in children with sickle cell disease.   
The underlying potential pathogenesis linking proteinuria and elevated pulmonary 
artery systolic pressures is unclear at this time.  Both complications occur in childhood 
with increasing prevalence with age (54, 55, 67, 68).  Both complications are risk factors 
for death in sickle cell disease patients (12, 16).  The risk factors for elevated pulmonary 
artery pressures are markers of hemolysis such as low hemoglobin, elevated reticulocyte 
count, elevated lactate dehydrogenase, and high hemolytic index.  The pathogenesis of 
elevated pulmonary artery pressures is thought to be multifactorial with hemolysis 
induced nitric oxide depletion and consequent vascular dysfunction playing a major role.  
Recently the role of inflammation has been described in the pathogenesis. 
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Albuminuria is common in sickle cell disease patients and is reported in 16–26% 
of children. Studies in adults with sickle cell disease report a 42% prevalence of 
albuminuria.  Risk factors associated with albuminuria include older age, type of sickle 
cell disease, history of acute chest syndrome, and serum creatinine (37, 55).  The 
association of low hemoglobin with albuminuria or proteinuria has varied in different 
reports.  Several investigators showed that albuminuria/proteinuria was associated with 
low hemoglobin (54, 57, 69, 70).  Others have not found an association between low 
hemoglobin and albuminuria (55, 57, 68).  However Ataga et al. did find that hemoglobin 
levels were lower and lactate dehydrogenase levels were higher in patients with 
macroalbuminuria compared to patients with microalbuminuria or normoalbuminuria, 
hence postulating that hemolysis may play a role in albuminuria in sickle cell disease 
(57).  Interestingly, they also found that the levels of sFLT-1, soluble VCAM, and NT 
pro-BNP were significantly higher in patients with macroalbuminuria as compared to 
patients with microalbuminuria or normoalbuminuria.  sFLT-1, a tyrosine kinase protein 
which inhibits VEGF, has also been shown to be associated with PHT.  The association 
between albuminuria and elevated pulmonary artery systolic pressures may be in part due 
to endothelial activation and endothelial dysfunction that is known to follow increased 
levels of sFLT-1. 
Our study of the association between elevated TRV and proteinuria has some 
limitations.  The data was collected retrospectively and in some patients the 
echocardiograms and urinalysis were not performed simultaneously. There were some 
missing urinalysis and echocardiogram data points.  Additionally, due to the nature of the 
available data we were only able to examine proteinuria, and were not able to quantify 
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microabinuria in the patient population that we studied.  The addition of microalbinuria 
data may have strengthened or further revealed important information about the potential 
association between elevated TRV and urinary protein.  Therefore, we recommend that a 
prospective study be conducted, ideally on a larger patient population across multiple 
clinical sites to further define this association and potentially examine the role of 
microalbinuria in addition to fulminant proteinuria. 
In conclusion, our second study shows that elevated TRV is associated with 
proteinuria in children with sickle cell disease.  The underlying pathogenesis linking the 
two conditions is currently being explored.  It is likely that hemolysis or inflammation 
induced endothelial dysfunction may play a role.   
 
  
33 
!
REFERENCES 
1. Hassell, K.L. 2010. Population estimates of sickle cell disease in the U.S. Am J 
Prev Med 38:S512-521. 
2. McCavit, T.L. 2012. Sickle cell disease. Pediatr Rev 33:195-204; quiz 205-196. 
3. Fixler, J., and Styles, L. 2002. Sickle cell disease. Pediatr Clin North Am 
49:1193-1210, vi. 
4. Serjeant, G.R. 1997. Sickle-cell disease. Lancet 350:725-730. 
5. Schnog, J.B., Duits, A.J., Muskiet, F.A., ten Cate, H., Rojer, R.A., and Brandjes, 
D.P. 2004. Sickle cell disease; a general overview. Neth J Med 62:364-374. 
6. Ballas, S.K., and Mohandas, N. 1996. Pathophysiology of vaso-occlusion. 
Hematol Oncol Clin North Am 10:1221-1239. 
7. Hebbel, R.P. 1997. Perspectives series: cell adhesion in vascular biology. 
Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 
99:2561-2564. 
8. Buchanan, G., Vichinsky, E., Krishnamurti, L., and Shenoy, S. 2010. Severe 
sickle cell disease--pathophysiology and therapy. Biol Blood Marrow Transplant 
16:S64-67. 
9. Scott, R.B. 1970. Health care priority and sickle cell anemia. JAMA 214:731-734. 
10. Vichinsky, E., Hurst, D., Earles, A., Kleman, K., and Lubin, B. 1988. Newborn 
screening for sickle cell disease: effect on mortality. Pediatrics 81:749-755. 
11. Powars, D.R., Chan, L.S., Hiti, A., Ramicone, E., and Johnson, C. 2005. Outcome 
of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine 
(Baltimore) 84:363-376. 
34 
!
12. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, 
M.H., and Klug, P.P. 1994. Mortality in sickle cell disease. Life expectancy and 
risk factors for early death. N Engl J Med 330:1639-1644. 
13. De Castro, L.M., Jonassaint, J.C., Graham, F.L., Ashley-Koch, A., and Telen, 
M.J. 2008. Pulmonary hypertension associated with sickle cell disease: clinical 
and laboratory endpoints and disease outcomes. Am J Hematol 83:19-25. 
14. Ataga, K.I., Sood, N., De Gent, G., Kelly, E., Henderson, A.G., Jones, S., 
Strayhorn, D., Lail, A., Lieff, S., and Orringer, E.P. 2004. Pulmonary 
hypertension in sickle cell disease. Am J Med 117:665-669. 
15. Castro, O., Hoque, M., and Brown, B.D. 2003. Pulmonary hypertension in sickle 
cell disease: cardiac catheterization results and survival. Blood 101:1257-1261. 
16. Gladwin, M.T., Sachdev, V., Jison, M.L., Shizukuda, Y., Plehn, J.F., Minter, K., 
Brown, B., Coles, W.A., Nichols, J.S., Ernst, I., et al. 2004. Pulmonary 
hypertension as a risk factor for death in patients with sickle cell disease. N Engl J 
Med 350:886-895. 
17. Currie, P.J., Seward, J.B., Chan, K.L., Fyfe, D.A., Hagler, D.J., Mair, D.D., 
Reeder, G.S., Nishimura, R.A., and Tajik, A.J. 1985. Continuous wave Doppler 
determination of right ventricular pressure: a simultaneous Doppler-
catheterization study in 127 patients. J Am Coll Cardiol 6:750-756. 
18. Berger, M., Haimowitz, A., Van Tosh, A., Berdoff, R.L., and Goldberg, E. 1985. 
Quantitative assessment of pulmonary hypertension in patients with tricuspid 
regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 
6:359-365. 
35 
!
19. Fitzgerald, M., Fagan, K., Herbert, D.E., Al-Ali, M., Mugal, M., and Haynes, J. 
2012. Misclassification of Pulmonary Hypertension in Adults with Sickle 
Hemoglobinopathies Using Doppler Echocardiography. Southern Medical 
Journal 105:300-305. 
20. Kato, G.J. 2012. TRV: a physiological biomarker in sickle cell disease. Pediatr 
Blood Cancer 58:831-832. 
21. Sutton, L.L., Castro, O., Cross, D.J., Spencer, J.E., and Lewis, J.F. 1994. 
Pulmonary hypertension in sickle cell disease. Am J Cardiol 74:626-628. 
22. Manci, E.A., Culberson, D.E., Yang, Y.M., Gardner, T.M., Powell, R., Haynes, J., 
Jr., Shah, A.K., Mankad, V.N., and Investigators of the Cooperative Study of 
Sickle Cell, D. 2003. Causes of death in sickle cell disease: an autopsy study. Br J 
Haematol 123:359-365. 
23. Adedeji, M.O., Cespedes, J., Allen, K., Subramony, C., and Hughson, M.D. 2001. 
Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch 
Pathol Lab Med 125:1436-1441. 
24. Haque, A.K., Gokhale, S., Rampy, B.A., Adegboyega, P., Duarte, A., and 
Saldana, M.J. 2002. Pulmonary hypertension in sickle cell hemoglobinopathy: a 
clinicopathologic study of 20 cases. Hum Pathol 33:1037-1043. 
25. Pashankar, F.D., Carbonella, J., Bazzy-Asaad, A., and Friedman, A. 2008. 
Prevalence and risk factors of elevated pulmonary artery pressures in children 
with sickle cell disease. Pediatrics 121:777-782. 
36 
!
26. Qureshi, N., Joyce, J.J., Qi, N., and Chang, R.K. 2006. Right ventricular 
abnormalities in sickle cell anemia: evidence of a progressive increase in 
pulmonary vascular resistance. J Pediatr 149:23-27. 
27. Minniti, C.P., Sable, C., Campbell, A., Rana, S., Ensing, G., Dham, N., 
Onyekwere, O., Nouraie, M., Kato, G.J., Gladwin, M.T., et al. 2009. Elevated 
tricuspid regurgitant jet velocity in children and adolescents with sickle cell 
disease: association with hemolysis and hemoglobin oxygen desaturation. 
Haematologica 94:340-347. 
28. Kassim, A.A., and Debaun, M.R. 2013. Sickle cell disease, vasculopathy, and 
therapeutics. Annu Rev Med 64:451-466. 
29. Machado, R.F., Barst, R.J., Yovetich, N.A., Hassell, K.L., Kato, G.J., Gordeuk, 
V.R., Gibbs, J.S., Little, J.A., Schraufnagel, D.E., Krishnamurti, L., et al. 2011. 
Hospitalization for pain in patients with sickle cell disease treated with sildenafil 
for elevated TRV and low exercise capacity. Blood 118:855-864. 
30. Strouse, J.J., and Heeney, M.M. 2012. Hydroxyurea for the treatment of sickle 
cell disease: efficacy, barriers, toxicity, and management in children. Pediatr 
Blood Cancer 59:365-371. 
31. Lanzkron, S., Strouse, J.J., Wilson, R., Beach, M.C., Haywood, C., Park, H., 
Witkop, C., Bass, E.B., and Segal, J.B. 2008. Systematic review: Hydroxyurea for 
the treatment of adults with sickle cell disease. Ann Intern Med 148:939-955. 
32. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., 
McMahon, R.P., and Bonds, D.R. 1995. Effect of hydroxyurea on the frequency 
37 
!
of painful crises in sickle cell anemia. Investigators of the Multicenter Study of 
Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332:1317-1322. 
33. Strouse, J.J., Lanzkron, S., Beach, M.C., Haywood, C., Park, H., Witkop, C., 
Wilson, R.F., Bass, E.B., and Segal, J.B. 2008. Hydroxyurea for sickle cell 
disease: a systematic review for efficacy and toxicity in children. Pediatrics 
122:1332-1342. 
34. Charache, S., Dover, G.J., Moore, R.D., Eckert, S., Ballas, S.K., Koshy, M., 
Milner, P.F., Orringer, E.P., Phillips, G., Jr., Platt, O.S., et al. 1992. Hydroxyurea: 
effects on hemoglobin F production in patients with sickle cell anemia. Blood 
79:2555-2565. 
35. Bridges, K.R., Barabino, G.D., Brugnara, C., Cho, M.R., Christoph, G.W., Dover, 
G., Ewenstein, B.M., Golan, D.E., Guttmann, C.R., Hofrichter, J., et al. 1996. A 
multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea 
therapy. Blood 88:4701-4710. 
36. Hillery, C.A., Du, M.C., Wang, W.C., and Scott, J.P. 2000. Hydroxyurea therapy 
decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and 
laminin. Br J Haematol 109:322-327. 
37. Pashankar, F.D., Carbonella, J., Bazzy-Asaad, A., and Friedman, A. 2009. 
Longitudinal follow up of elevated pulmonary artery pressures in children with 
sickle cell disease. Br J Haematol 144:736-741. 
38. Morris, C.R., Kato, G.J., Poljakovic, M., Wang, X., Blackwelder, W.C., Sachdev, 
V., Hazen, S.L., Vichinsky, E.P., Morris, S.M., Jr., and Gladwin, M.T. 2005. 
38 
!
Dysregulated arginine metabolism, hemolysis-associated pulmonary 
hypertension, and mortality in sickle cell disease. JAMA 294:81-90. 
39. Machado, R.F., and Gladwin, M.T. 2005. Chronic sickle cell lung disease: new 
insights into the diagnosis, pathogenesis and treatment of pulmonary 
hypertension. Br J Haematol 129:449-464. 
40. Rother, R.P., Bell, L., Hillmen, P., and Gladwin, M.T. 2005. The clinical sequelae 
of intravascular hemolysis and extracellular plasma hemoglobin: a novel 
mechanism of human disease. JAMA 293:1653-1662. 
41. Castro, O., and Gladwin, M.T. 2005. Pulmonary hypertension in sickle cell 
disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 
19:881-896, vii. 
42. Ataga, K.I., Moore, C.G., Hillery, C.A., Jones, S., Whinna, H.C., Strayhorn, D., 
Sohier, C., Hinderliter, A., Parise, L.V., and Orringer, E.P. 2008. Coagulation 
activation and inflammation in sickle cell disease-associated pulmonary 
hypertension. Haematologica 93:20-26. 
43. Niu, X., Nouraie, M., Campbell, A., Rana, S., Minniti, C.P., Sable, C., Darbari, 
D., Dham, N., Reading, N.S., Prchal, J.T., et al. 2009. Angiogenic and 
inflammatory markers of cardiopulmonary changes in children and adolescents 
with sickle cell disease. PLoS One 4:e7956. 
44. Falk, R.J., Scheinman, J., Phillips, G., Orringer, E., Johnson, A., and Jennette, 
J.C. 1992. Prevalence and pathologic features of sickle cell nephropathy and 
response to inhibition of angiotensin-converting enzyme. N Engl J Med 326:910-
915. 
39 
!
45. da Silva, G.B., Jr., Liborio, A.B., and Daher Ede, F. 2011. New insights on 
pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell 
nephropathy. Ann Hematol 90:1371-1379. 
46. McClellan, A.C., Luthi, J.C., Lynch, J.R., Soucie, J.M., Kulkarni, R., Guasch, A., 
Huff, E.D., Gilbertson, D., McClellan, W.M., and DeBaun, M.R. 2012. High one 
year mortality in adults with sickle cell disease and end-stage renal disease. Br J 
Haematol 159:360-367. 
47. Pham, P.T., Pham, P.C., Wilkinson, A.H., and Lew, S.Q. 2000. Renal 
abnormalities in sickle cell disease. Kidney Int 57:1-8. 
48. de Santis Feltran, L., de Abreu Carvalhaes, J.T., and Sesso, R. 2002. Renal 
complications of sickle cell disease: managing for optimal outcomes. Paediatr 
Drugs 4:29-36. 
49. Stallworth, J.R., Tripathi, A., and Jerrell, J.M. 2011. Prevalence, treatment, and 
outcomes of renal conditions in pediatric sickle cell disease. South Med J 
104:752-756. 
50. Scheinman, J.I. 2009. Sickle cell disease and the kidney. Nat Clin Pract Nephrol 
5:78-88. 
51. Ataga, K.I., and Orringer, E.P. 2000. Renal abnormalities in sickle cell disease. 
Am J Hematol 63:205-211. 
52. Sharpe, C.C., and Thein, S.L. 2011. Sickle cell nephropathy - a practical 
approach. Br J Haematol 155:287-297. 
40 
!
53. Aygun, B., Mortier, N.A., Smeltzer, M.P., Hankins, J.S., and Ware, R.E. 2011. 
Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. 
Pediatr Nephrol 26:1285-1290. 
54. McKie, K.T., Hanevold, C.D., Hernandez, C., Waller, J.L., Ortiz, L., and McKie, 
K.M. 2007. Prevalence, prevention, and treatment of microalbuminuria and 
proteinuria in children with sickle cell disease. J Pediatr Hematol Oncol 29:140-
144. 
55. Alvarez, O., Montane, B., Lopez, G., Wilkinson, J., and Miller, T. 2006. Early 
blood transfusions protect against microalbuminuria in children with sickle cell 
disease. Pediatr Blood Cancer 47:71-76. 
56. Wigfall, D.R., Ware, R.E., Burchinal, M.R., Kinney, T.R., and Foreman, J.W. 
2000. Prevalence and clinical correlates of glomerulopathy in children with sickle 
cell disease. J Pediatr 136:749-753. 
57. Ataga, K.I., Brittain, J.E., Moore, D., Jones, S.K., Hulkower, B., Strayhorn, D., 
Adam, S., Redding-Lallinger, R., Nachman, P., and Orringer, E.P. 2010. Urinary 
albumin excretion is associated with pulmonary hypertension in sickle cell 
disease: potential role of soluble fms-like tyrosine kinase-1. European Journal of 
Haematology 85:257-263. 
58. Lane, P.A., Buchanan, G.R., Desposito, F., Pegelow, C.H., Vichinsky, E.P., 
Wethers, D.L., Woods, G.M., Berkow, R.L., August, C.S., Corrigan, J., et al. 
2002. Health supervision for children with sickle cell disease. Pediatrics 109:526-
535. 
41 
!
59. Campbell, A., Minniti, C.P., Nouraie, M., Arteta, M., Rana, S., Onyekwere, O., 
Sable, C., Ensing, G., Dham, N., Luchtman-Jones, L., et al. 2009. Prospective 
evaluation of haemoglobin oxygen saturation at rest and after exercise in 
paediatric sickle cell disease patients. Br J Haematol 147:352-359. 
60. Preston, I.R. 2007. Clinical perspective of hypoxia-mediated pulmonary 
hypertension. Antioxid Redox Signal 9:711-721. 
61. Liem, R.I., Young, L.T., Lay, A.S., Pelligra, S.A., Labotka, R.J., and Thompson, 
A.A. 2010. Reproducibility of tricuspid regurgitant jet velocity measurements in 
children and young adults with sickle cell disease undergoing screening for 
pulmonary hypertension. Am J Hematol 85:741-745. 
62. Ataga, K.I., Moore, C.G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., 
and Orringer, E.P. 2006. Pulmonary hypertension in patients with sickle cell 
disease: a longitudinal study. Br J Haematol 134:109-115. 
63. Parent, F., Bachir, D., Inamo, J., Lionnet, F., Driss, F., Loko, G., Habibi, A., 
Bennani, S., Savale, L., Adnot, S., et al. 2011. A hemodynamic study of 
pulmonary hypertension in sickle cell disease. N Engl J Med 365:44-53. 
64. Anthi, A., Machado, R.F., Jison, M.L., Taveira-Dasilva, A.M., Rubin, L.J., 
Hunter, L., Hunter, C.J., Coles, W., Nichols, J., Avila, N.A., et al. 2007. 
Hemodynamic and functional assessment of patients with sickle cell disease and 
pulmonary hypertension. Am J Respir Crit Care Med 175:1272-1279. 
65. Ataga, K.I., Brittain, J.E., Jones, S.K., May, R., Delaney, J., Strayhorn, D., Desai, 
P., Redding-Lallinger, R., Key, N.S., and Orringer, E.P. 2011. Association of 
42 
!
soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis 
in sickle cell disease. Br J Haematol 152:485-491. 
66. Minniti, C.P., Taylor, J.G.t., Hildesheim, M., O'Neal, P., Wilson, J., Castro, O., 
Gordeuk, V.R., and Kato, G.J. 2011. Laboratory and echocardiography markers in 
sickle cell patients with leg ulcers. Am J Hematol 86:705-708. 
67. Dharnidharka, V.R., Dabbagh, S., Atiyeh, B., Simpson, P., and Sarnaik, S. 1998. 
Prevalence of microalbuminuria in children with sickle cell disease. Pediatr 
Nephrol 12:475-478. 
68. Guasch, A., Navarrete, J., Nass, K., and Zayas, C.F. 2006. Glomerular 
involvement in adults with sickle cell hemoglobinopathies: Prevalence and 
clinical correlates of progressive renal failure. J Am Soc Nephrol 17:2228-2235. 
69. McBurney, P.G., Hanevold, C.D., Hernandez, C.M., Waller, J.L., and McKie, 
K.M. 2002. Risk factors for microalbuminuria in children with sickle cell anemia. 
J Pediatr Hematol Oncol 24:473-477. 
70. Thompson, J., Reid, M., Hambleton, I., and Serjeant, G.R. 2007. Albuminuria and 
renal function in homozygous sickle cell disease: observations from a cohort 
study. Arch Intern Med 167:701-708. 
 
 
Pediatr Blood Cancer 2012;58:937–940
Proteinuria is Associated With Elevated Tricuspid Regurgitant Jet Velocity in
Children With Sickle Cell Disease
Suzanne Forrest, BA,1 Ashley Kim,2 Judith Carbonella, APRN,1 and Farzana Pashankar, MD1*
INTRODUCTION
Pulmonary hypertension (PHT) occurs in approximately one
third of adults with sickle cell disease (SCD) and is associated
with a significantly increased mortality [1–3]. The definitive
diagnosis of PHT is made by right heart catheterization, however
this is invasive. Pulmonary artery systolic pressures can be esti-
mated by measurement of tricuspid regurgitant jet velocity (TRV)
on echocardiogram. Studies in children report a 16–30% preva-
lence of elevated TRV ! 2.5 m/second on screening echocardio-
grams [4–6]. The pathogenesis of PHT is likely multifactorial
and several investigators have proposed that hemolysis induced
nitric oxide depletion and vascular dysfunction play a major role
[3,7–10]. More recent reports highlight the role of inflammation
in the pathogenesis of PHT [11,12].
Sickle cell nephropathy (SCN) is of significant concern in
adults with SCD and renal failure affects 12–21% of adults
with SCD [13,14]. One of the early manifestations of SCN is
proteinuria. The onset of proteinuria has been reported in early
childhood, and studies in children report a 16–26% prevalence of
microalbuminuria and a 6.2% prevalence of proteinuria [15–18].
Risk factors associated with albuminuria in children include older
age, low hemoglobin, history of acute chest syndrome (ACS), and
type of SCD. Recently a study in adults found a positive associa-
tion between albuminuria and PHT [19]. However, there are no
data in children on the potential association between kidney dys-
function manifested by proteinuria and elevated pulmonary artery
pressures. We hence conducted a study to determine if elevated
pulmonary artery systolic pressures estimated on echocardio-
grams was associated with proteinuria in children with SCD.
METHODS
A detailed retrospective chart review was conducted on a
cohort of SCD patients. Starting in June 2005, screening echo-
cardiograms were incorporated at our center as part of the annual
evaluation of children with Hb SS and Hb Sb0 thalassemia older
than 6 years of age. Screening echocardiograms were done when
patients were in steady state, at least 2 weeks after admission for
vaso-occlusive crises. TRV was measured by pulsed-wave and
continuous wave Doppler echocardiography. Multiple views
(apical four chamber, parasternal short axis, parasternal long
axis) were obtained to record optimal tricuspid Doppler flow
signals and a minimum of five sequential signals were recorded.
A peak TRV of !2.5 m/second equating to a pulmonary artery
pressure of at least 30 mmHg was considered to be elevated.
Other evaluations done during the visit included a detailed history,
complete physical examination and laboratory studies including
complete blood count, reticulocyte count, renal and liver function
tests and urinalysis. Urinalysis was sent for measurement of pro-
tein, which was quantified from 0 to 3þ. Urine protein 1þ
equaled 30 mg/dl, 2þ equaled 100 mg/dl, and 3þ equaled
!300 mg/dl in our laboratory. Urine protein of 1þ to 3þ was
considered positive, urine protein of 0 was considered negative.
On follow up, urinalysis was repeated at least annually. Echo-
cardiograms were repeated annually on patients with a baseline
TRV ! 2.5 m/second, and every 2 years on patients with normal
baseline TRV.
For this study, charts were reviewed from June 2005 to
July 2010. Patients who had a screening echocardiogram and a
urinalysis within 1 year were included in the study. Baseline data
collected included demographics, type of SCD, clinical history,
echocardiogram results, laboratory results, and urinalysis. Longi-
tudinal data from all subsequent echocardiograms and urinalyses
for each subject were also collected. Data were analyzed using
Chi square test for categorical variables and t-test for continuous
variables. The study was approved by the institutional review
board.
Background. Sickle cell disease (SCD) affects multiple organ
systems. Complications of SCD such as pulmonary hypertension
(PHT) and sickle cell nephropathy (SCN) are associated with an
increased mortality. Both PHT and SCN have some common risk
factors. In adults, PHT has been found to be associated with albu-
minuria, a manifestation of SCN. There is no data on this associa-
tion in children. We conducted a study to determine if elevated
pulmonary artery systolic pressures estimated on echocardiogram
was associated with proteinuria in children with SCD. Methods.
A detailed retrospective chart review was conducted on a cohort
of sickle cell patients screened with echocardiograms from
June 2005 to July 2010. Patients who had an initial screening
echocardiogram and urine analysis within 1 year were included.
Longitudinal data from all subsequent echocardiograms and urine
analyses were collected. Results. Eighty-five patients were included.
On initial echocardiograms 32.9% had an elevated tricuspid regur-
gitant jet velocity (TRV) !2.5 m/second. On follow up, in the 28
patients with elevated TRV, 49.27% of all repeat echocardiograms
showed persistent elevation. In the 57 patients with normal baseline
TRV, 73.6% of all repeat echocardiograms continued to have nor-
mal TRV. On initial screening 7.14% of patients with elevated TRV
had proteinuria compared to 1.75% without elevated TRV. On
follow up, 19.08% of repeat urinalysis had proteinuria in patients
with elevated baseline TRV compared to 12.35% in patients with
normal baseline TRV (P ¼ 0.04). Conclusions. Elevated TRV !
2.5 m/second is significantly associated with proteinuria on longi-
tudinal follow up in children with SCD. Pediatr Blood Cancer
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RESULTS
A total of 85 patients aged 6–21 years were included in the
study. Seventy-two patients had Hb SS disease and 13 patients
had Sb0 thalassemia. The male to female ratio was 1.36:1. The
mean age at initial screening echocardiogram was 12.16 years
with a SD 4.15 years. On initial screening echocardiograms, 28
of 85 patients (32.9%) had TRV ! 2.5 m/second. Table I shows
the baseline characteristics of patients with and without elevated
TRV. As shown in Table I, low daytime oxygen saturation, high
reticulocyte count, and high platelet count were significantly
associated with elevated TRV. Of the 28 patients with elevated
TRV, 2 patients (7.14%) had proteinuria compared to 1 of 57
patients (1.75%) with normal TRV.
Follow up data was available for 82 patients. Average follow
up time was 3.23 years (range 0.27–5.15 years). As shown in
Table II, 89.29% of patients with elevated TRV had repeat
echocardiograms compared to 86% of patients with normal
TRV. The number of follow up echocardiograms per patient was
2.76 in the high TRV group and 2.24 in the normal TRV group. In
the 28 patients with baseline high TRV, 49.27% of the repeat
echocardiograms (N ¼ 69) showed persistent elevation of
TRV ! 2.5 m/second. In the 57 patients with baseline TRV <
2.5 m/second, 73.6% of all repeat echocardiograms (N ¼ 110)
continued to have TRV < 2.5 m/second. Patients with a
TRV ! 2.5 m/second on initial echocardiogram had a significant-
ly higher chance of having repeat echocardiograms with
elevated TRV compared to patients with normal baseline TRV
(P ¼ 0.003).
As shown in Table III, when patients were grouped based on
their initial screening echocardiograms, follow up urinalysis data
was available in 92.86% of patients with elevated TRV and in
94.73% of patients with normal TRV. The number of follow up
urinalysis per patient was 6.17 in the high TRV group and 7.24 in
the normal TRV group. Of the 173 repeat urine analyses in
patients with elevated TRV, 19.08% were positive for proteinuria
TABLE I. Characteristics of Patients With and Without TRV on Baseline Screening Echocardiogram
Patient characteristics
Baseline TRV
P
<2.5 m/second
(n ¼ 57)
>2.5 m/second
(n ¼ 28)
Age at echocardiogram, mean # SD, y 11.72 # 3.93 13.04 # 4.45 0.17
Male gender, n (%) 33 (57.89) 16 (57.14) 0.86
Genotype, n (%)
SS 45 (78.9) 27 (96.43)
Sb0 12 (21.0) 1(3.57) 0.22
H/O acute chest syndrome, n (%) 23 (40.3) 16 (57.14) 0.15
Hydroxyurea, n (%) 12 (21.0) 5 (17.86) 0.78
Blood transfusion, n (%) 12 (21.0) 2 (7.14) 0.12
Stroke/abnormal TCD, n (%) 10 (7.5) 1 (3.57) 0.09
Systolic BP, mean # SD, mmHg 108.42 # 8.10 110.00 # 7.63 0.39
Oxygen saturation, mean # SD 97.28 # 2.45 95.56 # 4.46 0.02$
Hemoglobin, mean # SD, g/L 8.45 # 1.30 8.30 # 1.09 0.60
Hematocrit, mean # SD 24.49 # 4.13 23.11 # 3.50 0.13
Reticulocyte count, mean # SD 10.43 # 5.39 13.66 # 6.73 0.04$
WBC count (%103/ml), mean # SD 14.23 # 5.34 13.53 # 4.76 0.55
Platelet count, mean # SD 406.48 # 143.08 505.39 # 143.75 0.003$
LDH, mean # SD 648.21 # 254.30 650.50 # 255.18 0.98
Total bilirubin, mean # SD 3.25 # 2.50 3.90 # 2.51 0.30
Creatinine, mean # SD, mg/dl 0.52 # 0.16 0.48 # 0.16 0.33
Positive urine protein, n (%) 1 (1.75) 2 (7.14) 0.25
$P < 0.05.
TABLE II. Follow Up Echocardiograms in Patients With and Without Elevated TRV on Baseline Screening ECHO
Patients characteristics
Baseline TRV
P<2.5 (n ¼ 57) >2.5 (n ¼ 28)
Patients with follow-up ECHO, n (%) 49 (85.96%) 25 (89.29%)
Total number of echocardiograms 110 69
Number of echocardiograms per patient 2.24 2.76 0.029$
Number of patients with repeat echocardiograms
showing TRV >2.5 m/second (%)
15 (30.6%) 15 (60%)
Number of repeat echocardiograms with TRV >2.5 m/second, n (%) 29 (26.36%) 34 (49.27%) 0.003$
Number of repeat echocardiograms with TRV <2.5 m/second, n (%) 81 (73.6%) 35 (50.7%)
$P < 0.05.
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compared to 12.35% (51 of 413 urine samples) in patients with
normal baseline TRV (P ¼ 0.04).
As shown in Table IV, when patients were grouped based on
the presence of any echocardiogram (baseline or follow up) hav-
ing TRV " 2.5 m/second, follow up urinalysis were available in
95.35% of patients with elevated TRV and 92.86% of patients
with normal TRV. Of the 302 repeat urinalysis in patients with
any elevated TRV, 21.52% were positive for proteinuria compared
to 6.69% (19 of 284 urine samples) in patients with every
TRV < 2.5 m/second (P ¼ <0.001).
DISCUSSION
Our study shows that on initial screening echocardiogram
32.9% of patients had an elevated TRV " 2.5 m/second. Risk
factors associated with increased TRV were similar to our previ-
ous study [4] and included low daytime oxygen saturation, high
reticulocyte count, and high platelet count. Other studies have
shown a similar association between low daytime oxygen satura-
tion and elevated TRV [6,20]. Urine protein was present in 2
(7.14%) patients with TRV " 2.5 m/second compared to 1
(1.75%) patient with normal TRV. This was not statistically sig-
nificant, due to the small numbers in each group. Interestingly, the
patient with normal TRV who had proteinuria at baseline did have
a borderline high TRVof 2.4–2.7 m/second on initial echocardio-
gram. All of his subsequent echocardiograms showed a high
TRV > 3 m/second, hence it is likely that the pulmonary artery
pressures were evolving at the time of the initial echocardiogram.
On follow up, we found that patients with normal TRV at
baseline had a 73.6% likelihood of continuing to have normal
TRV on subsequent echocardiograms. In patients with baseline
elevated TRV, 49.27% of repeat echocardiograms showed persis-
tent elevation, while 50.7% of repeat echocardiograms were nor-
mal with TRV < 2.5 m/second. This observation highlights that
the reproducibility of TRV measurement is limited. This has been
previously shown by us and other investigators [21,22]. It is hence
important to repeat echocardiograms and ensure that the elevated
TRV is persistent before considering any intervention.
Follow up of urinalysis data showed a significant association
between proteinuria and elevated TRV, when patients were
grouped either based on their initial echocardiogram or on any
subsequent echocardiogram showing TRV " 2.5 m/second. A
positive association between proteinuria and PHT has been
reported previously in adults [19,23]. Ours is the first study show-
ing that proteinuria is associated with elevated TRV in children
with SCD.
The underlying potential pathogenesis linking proteinuria and
elevated pulmonary artery systolic pressures is unclear at present.
Both complications occur in childhood with increasing prevalence
with age [15–17,24]. Both complications are risk factors for death
in SCD patients [3,25]. The risk factors for elevated pulmonary
artery pressures are markers of hemolysis such as low hemoglo-
bin, elevated reticulocyte count, elevated LDH, and high hemo-
lytic index. The pathogenesis of elevated pulmonary artery
pressures is thought to be multifactorial with hemolysis induced
nitric oxide depletion and consequent vascular dysfunction play-
ing a major role. Recently the role of inflammation has been
described in the pathogenesis.
Albuminuria is common in SCD patients and is reported in
16–26% of children with SCD. Studies in adults with SCD report
a 42% prevalence of albuminuria. Risk factors associated with
albuminuria include older age, type of SCD, history of ACS, and
serum creatinine [16,21]. The association of low hemoglobin with
albuminuria or proteinuria has varied in different reports. Several
investigators showed that albuminuria/proteinuria was associated
with low hemoglobin [15,18,26,27]. Others have not found
an association between low hemoglobin and albuminuria
[16,19,24]. However Ataga et al. [19] did find that hemoglobin
levels were lower and lactate dehydrogenase levels were higher
in patients with macroalbuminuria compared to patients with
microalbuminuria or normoalbuminuria, hence postulating that
hemolysis may play a role in albuminuria in SCD. Interestingly,
they also found that the levels of s FLT-1, soluble VCAM, and NT
pro-BNP were significantly higher in patients with macroalbumi-
nuria as compared to patients with microalbuminuria or
normoalbuminuria. s FLT-1 has also been shown to be associated
TABLE III. Follow Up Urinalysis in Patients With and Without Elevated TRV on Baseline Screening ECHO
Patients characteristics
Baseline TRV
P<2.5 (n ¼ 57) >2.5 (n ¼ 28)
Patients with follow-up urinalysis, n (%) 54 (94.73%) 26 (92.86%)
Total number of urinalysis 413 173
Number of urinalysis per patient 7.24 6.17
Number of urinalysis with positive protein, n (%) 51 (12.35%) 33 (19.08%) 0.04#
#P < 0.05.
TABLE IV. Follow Up Urinalysis in Patients With and Without Elevated TRV on Any ECHO (Baseline or Follow Up)
Patients characteristics
Baseline TRV
P<2.5 (n ¼ 42) >2.5 (n ¼ 43)
Patients with follow-up urinalysis, n (%) 39 (92.86%) 41 (95.35%)
Total number of urinalysis 284 302
Number of urinalysis per patient 7.28 7.36
Number of urinalysis with positive protein, n (%) 19 (6.69%) 65 (21.52%) <0.001#
#P < 0.05.
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with PHT [28]. The association between albuminuria and elevated
pulmonary artery systolic pressures may be in part due to endo-
thelial activation and endothelial dysfunction that follow
increased levels of s FLT-1.
Our study has some limitations. The data were collected
retrospectively and in some patients the echocardiograms and
urinalysis were not performed simultaneously. There were some
missing urinalysis and echocardiogram data points. We hence
recommend doing a prospective study to further define this
association.
In conclusion, our study shows that elevated TRV is associated
with proteinuria in children with SCD. The underlying pathogen-
esis linking the two conditions is currently being explored and it
is likely that hemolysis or inflammation induced endothelial
dysfunction may play a role.
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HIGHLIGHT
by Gregory J. Kato, MD*y
TRV: A Physiological Biomarker in Sickle Cell Disease
(Commentary on Forrest et al., page 937)
C linical and translational research makes the biggest leapsin human disease when effective biomarkers are developed
and put into play. Effective biomarkers are often convenient
surrogate markers of clinical outcomes that dramatically speed
up the development of clinically useful interventions. They also
often point to new mechanistic pathways that open up opportu-
nities for new intervention strategies. The biomarkers may be
biochemical, physiological, imaging, or any other reproducible
indicator. Familiar examples of effective biomarkers that guide
clinical management resulting in improved clinical outcomes
include blood pressure, serum cholesterol, or tumor size from
radiographic imaging.
In sickle cell disease (SCD), the first truly successful biomark-
er was fetal hemoglobin [1]. Natural history epidemiological
investigation demonstrated that patients with higher levels suffer
fewer clinical complications of SCD. Bench investigations
showed that fetal hemoglobin inhibited polymerization of sickle
hemoglobin. Intervention with hydroxyurea raises fetal hemoglo-
bin levels, and improves clinical outcomes. Hydroxyurea is now
an approved, standard of care drug in SCD, and indications for its
prescription continue to expand.
The second truly successful biomarker in SCD is a physiolog-
ical biomarker: transcranial Doppler (TCD) velocity of blood flow
in the cerebral arteries [2]. TCD velocity predicts risk of stroke in
children with SCD. Therapeutic intervention with monthly trans-
fusion of red blood cells lowers the TCD velocity, and markedly
reduces the incidence of first stroke. Three very important lessons
emerged from TCD research. Successful application of TCD: (i)
occurred despite lack of consensus over the precise physiological
mechanism of TCD velocity; (ii) occurred despite known limita-
tions in its specificity; (iii) required highly standardized TCD
measurement conditions and specific technician training.
In this issue of Pediatric Blood & Cancer, Forrest et al. at Yale
University show that tricuspid regurgitant velocity (TRV) mea-
sured during Doppler echocardiography in children with SCD is a
biomarker that associates with proteinuria, a sign of renal disease.
In order to put this observation in perspective, it is helpful to trace
the findings that establish TRV as a physiological biomarker in
SCD.
Elevated TRV predicts mortality in adults with SCD more
strongly than any other marker. A longstanding marker of pulmo-
nary hypertension in the echocardiography world, TRV was first
introduced as a biomarker in SCD research by Sutton et al. [3] in
a retrospective study. Gladwin et al. [4] published a prospective
cross-sectional screening study of adults with SCD that showed
that a TRV of two standard deviations above the mean
(!2.5 m/second) was prevalent (32%), and predicted about a
10-fold risk for early mortality [4], findings confirmed by Ataga
et al. [5]. Both Gladwin and Ataga attributed the findings to
pulmonary hypertension, correct in principle. However, since
the consensus clinical definition of pulmonary hypertension uses
a threshold for diagnosis of mean pulmonary artery pressure three
standard deviations above the mean (25 mmHg) by right heart
catheterization, these differences in definitions have led to confu-
sion and debate [6]. Nevertheless, TRV is emerging as a robust
physiological biomarker of clinical outcome in SCD.
TRV in SCD adults reproducibly correlates with several im-
portant clinical outcomes. Several studies confirm that elevated
TRV in SCD adults is associated with important clinical
outcomes: pulmonary hypertension [7–9], proteinuria [10,11],
leg ulcers [4,7,12–15], decreased exercise capacity [8,16], and
early death [4,5]. TRV is one of several longstanding noninvasive
modalities for estimating pulmonary artery pressure in the fields
of echocardiography and pulmonary hypertension. This same as-
sociation has been documented by right heart catheterization
studies in SCD [8]. In adults, TRV !2.5 m/second has a positive
predictive value for pulmonary hypertension of only 25% [7],
although addition of NT-proBNP to the screening criteria may
help provide, respectable yields for a screening test. TRV can be a
useful screening tool in adults with SCD, especially if coupled
with a 6-minute walk distance <500 m [16,17].
To put these numbers in context, TCD velocity is highly useful
and now constitutes standard of care despite an estimated positive
predictive value of only 36% [18]. Like TRV, (i) there is lack of
consensus over the precise physiological mechanism of TCD
velocity [6]; (ii) there are limitations in its specificity; (iii) highly
standardized measurement conditions are required to minimize
variability [19].
It would be ideal to identify subjects at high risk to target
preventative strategies. Elevated TRV is detectable in childhood
[20], decades before the typical age at which pulmonary hyper-
tension becomes clinically symptomatic [21]. Elevated TRV in
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children with SCD is associated with many of the same clinical
features found in SCD adults with elevated TRV: higher systolic
blood pressure, lower hemoglobin, higher serum levels of biliru-
bin, and lactate dehydrogenase [20]. SCD children with elevated
TRV show a greater decline in systemic arterial oxygen saturation
during exercise than children without a TRV elevation [22].
Although it is not immediately associated with decreased exercise
capacity as it is in adults with SCD, elevated TRV in children with
SCD predicts future loss of exercise capacity [23].
Forrest et al. in this issue add another piece to this picture,
showing that abnormal TRV in children with SCD is associated
with proteinuria, a form of end organ disease seen also in SCD
adults with high TRV [10,11]. It appears at this point that child-
hood echocardiography screening might be identifying an early
stage of elevated TRV, but only long-term longitudinal cohort
studies will give the definitive answer. These children over years
or decades may be at risk to develop loss of exercise capacity and
potentially clinically significant pulmonary hypertension. More
research is needed in order to provide better evidence regarding
screening guidelines in children with SCD.
Children with SCD and elevated TRV may be an ideal group
for randomized controlled trials to test possible strategies to pre-
vent progression to high-risk status in adulthood. Such trials
might test hydroxyurea or other disease modifying strategies for
this indication. Since death with high TRV appears to occur
mainly in adulthood, such trials would need to use a more imme-
diate surrogate marker, such as exercise capacity, an endpoint
accepted by the Food and Drug Administration for approval of
pulmonary hypertension therapeutics. If and when an intervention
in presymptomatic children with high TRV is found that prevents
progression to adulthood pulmonary hypertension and death, TRV
will have fully followed in the footsteps of TCD as a physiologi-
cal biomarker of risk in children with SCD.
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